Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
<p>Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.</p>
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , , , , , , , , , |
| Veröffentlicht: |
2025
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1849927634275794944 |
|---|---|
| author | Tom Wei-Wu Chen (15053003) |
| author2 | Chia-Lang Hsu (11929719) Ruey-Long Hong (15053006) Jen-Chieh Lee (14954275) Koping Chang (15053009) Chih-Wei Yu (15053012) San-Chi Chen (15050106) Jhe-Cyuan Guo (15053015) Mei-Lu Chen (15053018) Meng-Chi Hsu (15053021) Ting-Fang Kung (15053024) Ann-Lii Cheng (15045786) Chueh-Chuan Yen (15053027) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Tom Wei-Wu Chen (15053003) Chia-Lang Hsu (11929719) Ruey-Long Hong (15053006) Jen-Chieh Lee (14954275) Koping Chang (15053009) Chih-Wei Yu (15053012) San-Chi Chen (15050106) Jhe-Cyuan Guo (15053015) Mei-Lu Chen (15053018) Meng-Chi Hsu (15053021) Ting-Fang Kung (15053024) Ann-Lii Cheng (15045786) Chueh-Chuan Yen (15053027) |
| author_role | author |
| dc.creator.none.fl_str_mv | Tom Wei-Wu Chen (15053003) Chia-Lang Hsu (11929719) Ruey-Long Hong (15053006) Jen-Chieh Lee (14954275) Koping Chang (15053009) Chih-Wei Yu (15053012) San-Chi Chen (15050106) Jhe-Cyuan Guo (15053015) Mei-Lu Chen (15053018) Meng-Chi Hsu (15053021) Ting-Fang Kung (15053024) Ann-Lii Cheng (15045786) Chueh-Chuan Yen (15053027) |
| dc.date.none.fl_str_mv | 2025-11-25T12:42:29Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30705876 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Supplementary_Figure_2_from_A_Single-Arm_Phase_Ib_II_Study_of_Lenvatinib_plus_Eribulin_in_Advanced_Liposarcoma_and_Leiomyosarcoma/30705876 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Sarcomas Soft-tissue sarcoma Translational Research |
| dc.title.none.fl_str_mv | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_f66f4f72e2db0b6b79d2a9515dcdd82f |
| identifier_str_mv | 10.1158/1078-0432.30705876 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30705876 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and LeiomyosarcomaTom Wei-Wu Chen (15053003)Chia-Lang Hsu (11929719)Ruey-Long Hong (15053006)Jen-Chieh Lee (14954275)Koping Chang (15053009)Chih-Wei Yu (15053012)San-Chi Chen (15050106)Jhe-Cyuan Guo (15053015)Mei-Lu Chen (15053018)Meng-Chi Hsu (15053021)Ting-Fang Kung (15053024)Ann-Lii Cheng (15045786)Chueh-Chuan Yen (15053027)CancerTherapeutic Research and DevelopmentClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsSarcomasSoft-tissue sarcomaTranslational Research<p>Cell type predictive of treatment efficacy. Cell type differences of (a) partial response vs non-partial responders (b) progression-free survival longer vs shorter than 6 months by MCP-Counter. All p-values were derived from non-parametric Wilcoxon test.</p>2025-11-25T12:42:29ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30705876https://figshare.com/articles/figure/Supplementary_Figure_2_from_A_Single-Arm_Phase_Ib_II_Study_of_Lenvatinib_plus_Eribulin_in_Advanced_Liposarcoma_and_Leiomyosarcoma/30705876CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307058762025-11-25T12:42:29Z |
| spellingShingle | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma Tom Wei-Wu Chen (15053003) Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Sarcomas Soft-tissue sarcoma Translational Research |
| status_str | publishedVersion |
| title | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| title_full | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| title_fullStr | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| title_full_unstemmed | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| title_short | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| title_sort | Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma |
| topic | Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase II clinical trials Sarcomas Soft-tissue sarcoma Translational Research |